Skip to main content
. Author manuscript; available in PMC: 2013 Dec 1.
Published in final edited form as: Lancet Neurol. 2012 Nov 6;11(12):10.1016/S1474-4422(12)70227-2. doi: 10.1016/S1474-4422(12)70227-2

Figure 2. Comparison of florbetapir (18F) levels in asymptomatic participants and non-carriers.

Figure 2

Statistical map showing significantly greater cortical-to-pontine florbetapir standard uptake value ratios in 19 asymptomatic mutation carriers compared with 20 non-carriers. The pattern of cortical amyloid-β deposition is similar to that reported in patients with late-onset Alzheimer’s disease. See Online for appendix